A Covid-19 vaccine will go into production while researchers are still studying if it works, under an ambitious plan by NIH’s Anthony S. Fauci to get a vaccine across the finish line in record time.
The proposal to start ramping up production while the candidate is still in a clinical trial is a risky step for a manufacturer, which would have to start assembling raw materials to make a vaccine without knowing whether it would work.
But the plan would make sure a vaccine is ready for patients if Covid-19, the disease caused by the new coronavirus, comes back next ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.